Metronidazole News and Research

RSS

Is it safe to drink alcohol when taking antibiotics?

In the lead up to summer party season, NPS MedicineWise is reminding Australians that while alcohol might not interact with many antibiotics, it’s still important to follow certain rules for taking antibiotics correctly.

15 Nov 2012

C. diff infections on the rise among children, elderly

Clostridium difficile infections are becoming more common and more severe in hospitalized children and the elderly, in large part due to greater use of antibiotics, Mayo Clinic researchers report in studies being presented at the American College of Gastroenterology annual meeting.

23 Oct 2012

Novel therapy that uses human stool is safe and highly effective in treating C.diff infection

A novel therapy that uses donated human stool to treat the deadly and contagious C.diff infection is safe and highly effective, according to a Henry Ford Hospital study.

20 Oct 2012

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds.

6 Sep 2012

RA drug effective against Entamoeba histolytica

Research by a collaborative group of scientists from UC San Diego School of Medicine, UC San Francisco and Wake Forest School of Medicine has led to identification of an existing drug that is effective against Entamoeba histolytica. This parasite causes amebic dysentery and liver abscesses and results in the death of more than 70,000 people worldwide each year.

21 May 2012

Auranofin effective against amoebas in lab and animal studies

A team of researchers from UCSF and UC San Diego has identified an approved arthritis drug that is effective against amoebas in lab and animal studies, suggesting it could offer a low-dose, low cost treatment for the amoebic infections that cause human dysentery throughout the world.

21 May 2012

New diagnostic test for Trichomonas vaginalis

Medical Diagnostic Laboratories, L.L.C. is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

2 Apr 2012

Cancer patients with CDI may benefit from DIFICLIR drug

New data presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrate that in cancer patients with CDI, DIFICLIR(fidaxomicin) may offer significant benefits in terms of clinical cure, recurrence and sustained clinical cure.

31 Mar 2012

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced positive top-line results from the recently completed Phase 2 studies of its CXA-201 and CB-183,315 antibiotic pipeline candidates. CXA-201 was studied for the treatment of complicated intra-abdominal infections (cIAI) in adults.

16 Jun 2011

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

Biota Holdings Limited advises that its wholly owned subsidiary, Biota Scientific Management Pty Ltd, has been awarded a grant to fund the preclinical development of a lead candidate for the treatment of Clostridium difficile (C. difficile).

10 Jun 2011

Australians discover treatment for very common female infection

Starpharma Holdings Limited has announced successful results of a major phase 2 clinical study that demonstrated efficacy of VivaGel® for the treatment of bacterial vaginosis (BV).

22 May 2011

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

ViroPharma Incorporated today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI.

20 May 2011

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Optimer Pharmaceuticals today announced the presentation of an additional analysis of data from the company's two Phase 3 clinical trials of DIFICID, an investigational antibiotic for the treatment of Clostridium difficile Infection, at the American Geriatric Society (AGS) Annual Meeting held in National Harbor, Maryland.

13 May 2011

Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 2011 Digestive Disease Week conference highlighting additional analyses of data from Phase 3 trials of DIFICID, an investigational product for the treatment of Clostridium difficile infection.

11 May 2011

Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference

Optimer Pharmaceuticals, Inc. today announced the presentation of two abstracts at the 21st European Congress of Clinical Microbiology and Infectious Diseases conference in Milan, Italy highlighting additional analyses of the Phase 3 data of DIFICID for the treatment of Clostridium difficile infection.

11 May 2011

China Sky One Medical first quarter total revenue decreases 1.9% to $28.4 million

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company in the People's Republic of China, today announced financial results for the first quarter of 2011.

11 May 2011

Scientists develop new test for premature babies

Scientists at Queen's University Belfast have pioneered a new needle-free test to take the sting out of medicine testing in premature babies. The research will not only lead to greater accuracy in prescribing, but will also significantly reduce the trauma of such tests for newborn infants and their families.

15 Apr 2011

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Optimer Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc. today announced the signing of an exclusive two-year co-promotion agreement to market DIFICID, in the United States.

6 Apr 2011

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

Optimer Pharmaceuticals, Inc. announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium difficile infection.

4 Apr 2011

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Optimer Pharmaceuticals, announced The New England Journal of Medicine has published results from the North American Phase 3 trial evaluating the safety and efficacy of the Company's novel antibiotic fidaxomicin as a treatment for patients with Clostridium difficile infection.

3 Feb 2011

Metronidazole News and Research

Is it safe to drink alcohol when taking antibiotics?

C. diff infections on the rise among children, elderly

Novel therapy that uses human stool is safe and highly effective in treating C.diff infection

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

RA drug effective against Entamoeba histolytica

Auranofin effective against amoebas in lab and animal studies

New diagnostic test for Trichomonas vaginalis

Cancer patients with CDI may benefit from DIFICLIR drug

Positive results from Cubist CXA-201 and CB-183,315 Phase 2 studies for complicated intra-abdominal infections

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

Australians discover treatment for very common female infection

ViroPharma commences VP 20621 Phase 2 study for prevention of recurrent Clostridium difficile infection

Two DIFICID Phase 3 trial data in C. difficile infection presented at AGS Annual Meeting

Two DIFICID Phase 3 trial data in C. difficile presented at DDW conference

Two DIFICID Phase 3 study data in C. difficile presented at ECCMID conference

China Sky One Medical first quarter total revenue decreases 1.9% to $28.4 million

Scientists develop new test for premature babies

Optimer, Cubist sign deal to market DIFICID for CDI treatment in the U.S.

Optimer study highlights economic burden of acute and recurrent CDI in hospital patients

New England Journal publishes fidaxomicin Phase 3 trial results against CDI

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News